-
AZD0156 ATM Kinase Inhibitor Workflow Guide
2026-09-10
Learn how to use AZD0156 to dissect ATM-dependent DNA damage signaling, optimize DNA double-strand break repair assays, and test cancer-cell sensitization workflows. The guide combines practical assay parameters, orthogonal readouts, reference-informed pharmacology, and troubleshooting for reproducible checkpoint control modulation.
-
D-Luciferin Sodium Salt for CAR-M Assays
2026-09-10
D-Luciferin sodium salt connects firefly luciferase reporting with rigorous CAR macrophage assay design. Learn how ATP-dependent light output can support cell viability and metabolism monitoring without confusing reporter signal with therapeutic mechanism.
-
Etoposide (VP-16): From DNA Damage to Translation
2026-09-09
Etoposide (VP-16) is more than a cytotoxic reference compound: it is a mechanistically defined probe for connecting topoisomerase II trapping with DNA double-strand break signaling, apoptosis, and translational model selection. This article presents a practical framework for deploying Etoposide in DNA damage assays, cancer chemotherapy research, and adjacent senescence biology while distinguishing established evidence from forward-looking applications.
-
PreScission Protease (PSP) Protocol Guide
2026-09-09
PreScission Protease (PSP) provides site-directed removal of compatible affinity tags from recombinant fusion proteins through HRV 3C protease activity. It is appropriate when the defined cleavage sequence is present and accessible, but it should not be treated as a general-purpose protease or used without optimization when the junction, buffer, or target stability is uncertain.
-
Human SAN-Plexus Assembloids and Pacemaker Maturation
2026-09-08
The reference study introduces human pluripotent stem cell-derived SAN-plexus assembloids that combine pacemaker, cardiac neural, and atrial-like tissues to model innervation-associated maturation. By integrating electrophysiology with human SAN spatial transcriptomics, the work identifies a prosaposin–GPR37 signaling program and provides a platform for studying neuro-cardiac control and conduction dysfunction.
-
Dorsomorphin 2HCl for AMPK Assay Design
2026-09-08
Dorsomorphin 2HCl is an AMPK inhibitor that can separate pathway dependence from correlation in metabolic studies. This article explains how to use its AMPK and BMP activities to design more rigorous liver, osteogenesis, and iron-homeostasis assays.
-
Neuromedin S (rat): Practical GPCR Guide
2026-09-07
Neuromedin S (rat) is a defined endogenous peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, assay setup, quality control, and interpretation limits; the reagent is for scientific research only and is not intended for diagnostic, therapeutic, or medical use.
-
Cy5 TSA Fluorescence System Kit: Lab Guide
2026-09-05
A scenario-driven guide to using the Cy5 TSA Fluorescence System Kit (SKU K1052) for sensitive immunocytochemistry, immunohistochemistry, and in situ hybridization workflows. It explains assay design, protocol parameters, controls, interpretation, and practical criteria for selecting a reliable fluorescent signal amplification kit.
-
TLR4, NLRP3, and Coagulation in Endotoxemia
2026-09-05
Sachetto and colleagues dissected how TLR4, caspase-11, NLRP3, and caspase-1 contribute to tissue factor-positive extracellular vesicle activity and coagulation after LPS challenge. Their results identify TLR4 as the dominant pathway, while caspase-11 and NLRP3 make smaller, predominantly late contributions that are separable from caspase-1-dependent inflammatory signaling.
-
ATM Inhibition and Fenofibrate in HGSOC
2026-09-04
The reference study identifies a metabolic vulnerability in high-grade serous ovarian cancer by showing that ATM inhibition synergizes with fenofibrate, a PPARα agonist, in HGSOC cell models. Its integrated use of tumor-expression analysis, Dependency Map drug sensitivity data, and functional validation provides a rationale for combining DNA damage response inhibition with metabolic intervention, particularly in homologous-recombination-proficient disease.
-
SIRT4, Glutamine Metabolism, and Liver Fibrosis
2026-09-04
The reference study identifies SIRT4-mediated control of glutamate dehydrogenase as a metabolic brake on hepatic stellate-cell activation and liver fibrosis. By combining glutamine-metabolism inhibition with in vitro and in vivo fibrosis experiments, it links mitochondrial glutamine catabolism to extracellular-matrix production and highlights SIRT4 as a potential antifibrotic target.
-
(S)-(+)-Dimethindene maleate: M2 Workflow
2026-09-03
This dossier-based guide explains how (S)-(+)-Dimethindene maleate can be incorporated into controlled receptor pharmacology workflows involving M2 muscarinic and histamine H1 antagonism. It is a research reagent, not a diagnostic or medical product, and the recommendations below should not be interpreted as directly matched literature evidence or clinical guidance.
-
AZD1480 and the Tumor-Protective JAK2/STAT3 Axis
2026-09-03
A translational framework for using AZD1480 to interrogate tumor-intrinsic JAK2/STAT3 survival signaling that may emerge during IDO1-directed immunometabolic therapy.
-
IGF2BP3–RCC2 m6A Axis in AML Progression
2026-09-02
The reference study identifies IGF2BP3 as an overexpressed m6A reader that supports acute myeloid leukemia by stabilizing m6A-modified RCC2 mRNA. Its combination of clinical expression analysis, mechanistic RNA studies, cellular assays, and in vivo validation places the IGF2BP3–RCC2 pathway among the potentially actionable regulatory circuits in high-risk AML.
-
AG-126 for ERK Signaling Research
2026-09-02
AG-126 (Tyrphostin AG-126) provides a practical ERK1/2 perturbation tool for phospho-ERK assays, cytokine studies, and carefully controlled neurobiology experiments. This guide translates its reported inflammatory use into workflow-ready design while clearly separating established evidence from exploratory applications in striatal D2-MSN research.